BCX 4430 hydrochloride

Category	Filovirus
CAS	222631-44-9
Description	BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. BCX4430 may be suitable for administration by intravenous (IV), intramuscular (IM), and oral (PO) routes.

Quotation Now

Product Information

Synonyms	BCX-4430; BCX 4430; BCX4430; Immucillin-A hydrochloride; Immucillin A hydrochloride
Molecular Weight	301.73
Molecular Formula	C11H16ClN5O3
Canonical SMILES	C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O.Cl
InChI	InChI=1S/C11H15N5O3.ClH/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7;/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15);1H/t5-,7+,9-,10+;/m1./s1
InChIKey	PCCHVYNGFMEGIG-QPAIBFMUSA-N
Purity	>98%
Solubility	In Vitro: DMSO : 105 mg/mL(347.99 mM;Need ultrasonic) H2O : ≥ 41 mg/mL(135.88 mM) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 5.25 mg/mL (17.40 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 5.25 mg/mL (17.40 mM); Clear solution
Appearance	White to off-white (Solid)
Storage	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture)
Complexity	334
Exact Mass	301.0941671
In Vitro	Cellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination. Galidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM).
In Vivo	Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir (BCX4430) hydrochloride has demonstrated pronounced efficacy. Galidesivir (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF).
Target	DNA/RNA Synthesis; SARS-CoV; Filovirus